Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Similar articles for PubMed (Select 22987135)

1.

[Catecholaminergic polymorphic ventricular tachycardia].

Frommeyer G, Pott C, Schulze-Bahr E, Eckardt L.

Herzschrittmacherther Elektrophysiol. 2012 Sep;23(3):231-6. doi: 10.1007/s00399-012-0224-8. Epub 2012 Sep 18. German. Erratum in: Herzschrittmacherther Elektrophysiol. 2012 Dec 23(4):357.

PMID:
22987135
2.

Catecholaminergic polymorphic ventricular tachycardia in a child: a case report.

Garabedian L, Verryckt A, Panzer J, De Wolf D.

Acta Paediatr. 2008 Jan;97(1):127-9. Epub 2007 Dec 3.

PMID:
18052993
3.

Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.

Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, Cruz Filho FE, Vignati G, Benatar A, DeLogu A.

Circulation. 2002 Jul 2;106(1):69-74.

4.

Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.

Pflaumer A, Davis AM.

Heart Lung Circ. 2012 Feb;21(2):96-100. doi: 10.1016/j.hlc.2011.10.008. Epub 2011 Nov 25. Review.

PMID:
22119737
5.

Catecholaminergic polymorphic ventricular tachycardia.

Francis J, Sankar V, Nair VK, Priori SG.

Heart Rhythm. 2005 May;2(5):550-4. Review.

PMID:
15840485
6.

Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.

Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, Klug D, Hayashi M, Takatsuki S, Villain E, Kamblock J, Messali A, Guicheney P, Lunardi J, Leenhardt A.

Circulation. 2009 May 12;119(18):2426-34. doi: 10.1161/CIRCULATIONAHA.108.829267. Epub 2009 Apr 27.

7.

Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights.

Kontula K, Laitinen PJ, Lehtonen A, Toivonen L, Viitasalo M, Swan H.

Cardiovasc Res. 2005 Aug 15;67(3):379-87. Review.

8.

Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.

Sy RW, Gollob MH, Klein GJ, Yee R, Skanes AC, Gula LJ, Leong-Sit P, Gow RM, Green MS, Birnie DH, Krahn AD.

Heart Rhythm. 2011 Jun;8(6):864-71. doi: 10.1016/j.hrthm.2011.01.048. Epub 2011 Feb 9.

PMID:
21315846
9.
10.

A case of catecholaminergic polymorphic ventricular tachycardia caused by two calsequestrin 2 mutations.

de la Fuente S, Van Langen IM, Postma AV, Bikker H, Meijer A.

Pacing Clin Electrophysiol. 2008 Jul;31(7):916-9. doi: 10.1111/j.1540-8159.2008.01111.x.

PMID:
18684293
11.

The phenotype of a CASQ2 mutation in a Saudi family with catecholaminergic polymorphic ventricular tachycardia.

Al-Hassnan ZN, Tulbah S, Al-Manea W, Al-Fayyadh M.

Pacing Clin Electrophysiol. 2013 May;36(5):e140-2. doi: 10.1111/j.1540-8159.2012.03434.x. Epub 2012 May 31.

PMID:
22650415
12.

Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond.

Katz G, Arad M, Eldar M.

Curr Probl Cardiol. 2009 Jan;34(1):9-43. doi: 10.1016/j.cpcardiol.2008.09.002. Review.

PMID:
19068246
13.

Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia.

Heiner JD, Bullard-Berent JH, Inbar S.

Pediatr Emerg Care. 2011 Nov;27(11):1065-8. doi: 10.1097/PEC.0b013e3182360606.

PMID:
22068070
14.

Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives.

van der Werf C, Nederend I, Hofman N, van Geloven N, Ebink C, Frohn-Mulder IM, Alings AM, Bosker HA, Bracke FA, van den Heuvel F, Waalewijn RA, Bikker H, van Tintelen JP, Bhuiyan ZA, van den Berg MP, Wilde AA.

Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):748-56. doi: 10.1161/CIRCEP.112.970517. Epub 2012 Jul 10.

15.

Clinical characteristics and mutational analysis of the RyR2 gene in seven Czech families with catecholaminergic polymorphic ventricular tachycardia.

Andrsova I, Valaskova I, Kubus P, Vit P, Gaillyova R, Kadlecova J, Manouskova L, Novotny T.

Pacing Clin Electrophysiol. 2012 Jul;35(7):798-803. doi: 10.1111/j.1540-8159.2012.03399.x. Epub 2012 Apr 22.

PMID:
22519458
16.

Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.

Pott C, Dechering DG, Reinke F, Muszynski A, Zellerhoff S, Bittner A, Köbe J, Wasmer K, Schulze-Bahr E, Mönnig G, Kotthoff S, Eckardt L.

Europace. 2011 Jun;13(6):897-901. doi: 10.1093/europace/euq517. Epub 2011 Feb 2. Review.

17.

Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death.

Terentyev D, Nori A, Santoro M, Viatchenko-Karpinski S, Kubalova Z, Gyorke I, Terentyeva R, Vedamoorthyrao S, Blom NA, Valle G, Napolitano C, Williams SC, Volpe P, Priori SG, Gyorke S.

Circ Res. 2006 May 12;98(9):1151-8. Epub 2006 Apr 6.

18.

Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia.

Song L, Alcalai R, Arad M, Wolf CM, Toka O, Conner DA, Berul CI, Eldar M, Seidman CE, Seidman JG.

J Clin Invest. 2007 Jul;117(7):1814-23.

19.

Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.

Rosso R, Kalman JM, Rogowski O, Diamant S, Birger A, Biner S, Belhassen B, Viskin S.

Heart Rhythm. 2007 Sep;4(9):1149-54. Epub 2007 May 24.

PMID:
17765612
20.

Catecholaminergic polymorphic ventricular tachycardia.

Liu N, Colombi B, Raytcheva-Buono EV, Bloise R, Priori SG.

Herz. 2007 May;32(3):212-7. Review.

PMID:
17497254
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk